HLA-G, a natural immunosuppressant present in the human placenta during pregnancy, prevents fetal destruction by the maternal immune system. The immunosuppressive effect of HLA-G is mediated by the immune cell inhibitory receptors, LILRB1 and LILRB2. HLA-G forms disulfide-linked dimers by natural oxidation, and the dimer associates with LILRB1/B2 much more strongly than the monomer. Furthermore, the dimer formation remarkably enhanced the LILRB-mediated signaling. In this report, we studied the in vivo immunosuppressive effect of the HLA-G dimer, using the collagen-induced arthritis model mice. Mice were treated with the HLA-G monomer or dimer intracutaneously at the left foot joint, once or for 5 days, and the clinical severity was evaluated daily in a double-blind study. The HLA-G monomer and dimer both produced excellent anti-inflammatory effects with a single, local administration.
Clinically, HLA-G dysfunction causes pregnancy disorders, such as recurrent miscarriages and preeclampsia [4] . The pathological relevance of HLA-G was also found in transplantation, infectious diseases, autoimmune diseases, inflammatory diseases and cancers [5] . For example, in patients with rheumatoid arthritis (RA), asthma, or multiple sclerosis, the soluble HLA-G plasma levels and the HLA-G expression in monocytes are reduced [5] . The HLA-G molecule has been proposed as a new reagent, in combination with currently used immunosuppressive drugs, to improve allograft acceptance [6] . The genetically engineered form of HLA-G has been patented (EP1328290A2), and thus HLA-G could be administered to women with fertility problems. The administration of HLA-G negatively regulated the LILRB1-mediated 4 immune response, to suppress allo-immune responses in LILRB1 transgenic mice [7] .
In a previous study, we found that a disulfide-linked HLA-G dimer mediates much more efficient signals than HLA-G monomers by binding to LILRB1 and LILRB2, thus enabling one HLA-G dimer to bind two receptors simultaneously [8] . Dimerization positions the intracellular domains of the receptors close to each other, thus supporting highly efficient signaling. Therefore, the recombinant HLA-G dimer is expected to function as a potent anti-inflammatory reagent.
We have assessed the immunosuppressive effects of the HLA-G monomer and dimer, using collagen-induced arthritis (CIA) in DBA/1 mice, a typical animal model for studying the pathogenic mechanisms of RA. We found that the HLA-G monomer and dimer both exhibited excellent anti-inflammatory activity, with the dimer displaying much more significant anti-rheumatoid arthritis activity than the monomer, without apparent side effects. These effects were mediated through the mouse LILRB homologue, a paired immunoglobulin-like receptor (PIR)-B that binds to HLA-G, as previously reported [9, 10] . The present in vitro binding study revealed that the dimer shows a remarkable avidity effect for PIR-B binding, resulting in much higher affinity than the monomer, which ensures the strong anti-RA activity. From these findings, the HLA-G monomer or dimer might be useful as a new immunosuppressive agent, with small amounts resulting in long-term, persistent effects.
Materials and methods

2.1.Expression and purification of the HLA-G and PIR-B proteins
Site-directed mutagenesis of HLA-G was performed by PCR, using the forward primer HLA-GF (5′-ATGGGTAGTCATAGTATGCGTTAT-3′) and the reverse primer HLA-GR 
2.2.Mice
The male DBA/1J mice (6 weeks old) used in this study were purchased from Japan Charles River Breeding Laboratories (Yokohama, Japan), and were housed under specific pathogen-free conditions. All animal experiments were performed with the approvals of the Animal Care and Use Committee of Kyushu University and the Committee for Animal Research at Hokkaido University. 
2.3.Induction of CIA
2.4.Treatment of CIA
The clinical severity of the mice was evaluated daily, after additional sensitization. The RA scores were judged according to the criteria based on the evidence of arthritis at the large joint of the limbs (0: no swelling, 3: detectable swelling, 4: non-severe swelling, 5:
severe swelling), and at the small joints of the fingers (1 point for each finger). The maximum score per limb was 10, and that per mouse was 40. The body weight was measured daily, to consider the side effects. The treatment of the clinical score was evaluated daily, in a double-blind study.
2.5.Treatment with HLA-G proteins
In each experiment, 50 mice are sensitized with type-II collagen and mice which developed initial arthritis symptoms were selected to analyze. They were treated intracutaneously with the HLA-G monomer or dimer in PBS, at the left foot joint, either once or daily for 5 days. PBS was used as a negative control.
For sequential administration of HLA-G monomer, 20 mice (RA score; 3 to 9) were analyzed and for single administration of three doses of HLA-G monomer/dimer, 14 mice (RA score; 3) were analyzed. 
2.6.Statistical analysis
The data are presented as the mean ± SD in Figure 2 . Statistical analyses were done using StatView version 5.0 for Windows (Abacus Concepts Inc., Berkeley, CA, USA). P < 0.05 was considered to be statistically significant.
2.7.Surface Plasmon Resonance (SPR).
SPR experiments were performed with a BIAcore3000 ( 
Results
3.1.Effects of HLA-G monomer on the CIA mice
A preliminary study using the antigen-induced dermatitis mice showed that swabs of 9g of HLA-G monomer for 21 days exerted some anti-inflammatory effect (data not shown). In the present study, we administered the larger amount of HLA-G monomer (35g) a day to mice for five days with expectations for more immediate and apparent immunosuppressive effects. The clinical arthritis score was evaluated in a double-blind study. At 13 days after the additional sensitization, 20 mice (RA scores: 3-9) were selected and grouped into the control (PBS) and HLA-G monomer groups (10 mice each, RA score average: 5.1 in each group). The mice were treated with the HLA-G 8 monomer or PBS once a day for 5 days. As shown in Figure 2A , the treatment with the HLA-G monomer inhibited the joint swelling in the mice for several days. Interestingly, the effect was observed for all limbs, despite the local administration at the left foot joint ( Figure 2B ).
3.2.The HLA-G dimer exerted stronger effects in the CIA mice
Next, we studied the in vivo anti-inflammatory effect of HLA-G dimer formation. As shown in Figure 2 , the inhibition of RA symptoms was clearly observed after the sequential treatment with the 35g/day of HLA-G monomer. We could expect that the HLA-G dimer possesses stronger effects from the in vitro study [8] . Therefore, we tried single local injections of HLA-G proteins, and tested the optimal dosage (150 g, 15 g,
g per mouse).
In this comparison, the mice (7 individuals) that had an RA score of 3 at 13 days after the additional sensitization were classified as the "early onset group", and the mice (7 individuals) that had an RA score of 3 or 4 at 28 days after the additional sensitization were classified as the "late onset group". The following experiments were performed for these two groups.
In the early onset group, treatments with 150 g of HLA-G monomer and dimer strongly exhibited the anti-RA effect for about two months ( Figure 3A) . As for the 15 g treatment, the HLA-G dimer maintained a clear anti-rheumatoid arthritis effect comparable to that of 150 g of dimer; however, the HLA-G monomer showed only a modest effect with a shorter duration than the dimer ( Figure 3B ). In the mice treated with 1.5 g, neither the monomeric nor dimeric HLA-G showed any anti-RA symptoms ( Figure 3C ). The single administration of HLA-G sufficiently suppressed joint swelling, at a single dose of 15 μg for the dimer and 150 μg for the monomer in the early onset group, and these effects lasted for more than one month.
In the late onset group, the effective HLA-G dose for suppressing joint swelling was 9 less than that for the early onset group, which might possess a lower threshold of disease susceptibility. The HLA-G monomer and dimer suppressed joint swelling more effectively than the control (PBS) at doses of 150 μg/mouse and 15 μg/mouse ( Figure   4A, B) . The HLA-G dimer also had a joint swelling suppressing effect at a dose of 1.5
μg/mouse, whereas the HLA-G monomer did not show any suppressive effect at the same dose, as evidenced by the presence of joint swelling similar to that in the control ( Figure 4C ). These results thus demonstrated that the single administration of HLA-G can sufficiently suppress joint swelling, at a single dose of 1.5 μg for the dimer and 15
μg for the monomer in the rheumatoid arthritis late onset group, and these effects lasted for at least 50 days.
We showed that the HLA-G dimer provided a longer effect than the monomer, with a single HLA-G dose at concentrations at least several-fold lower than that of the monomer. The experiments also confirmed that the local intracutaneous administration of the HLA-G proteins to the left foot could suppress joint swelling in all four limbs (data not shown). Furthermore, the HLA-G monomer and dimer produced no side effects attributed to the HLA-G administration, as assessed by the common conditions and the body weights of the mice (data not shown). From these results, the single administration of HLA-G monomer and dimer at the appropriate time seemed to be enough to inhibit the initial symptoms of inflammation. These immunosuppressive effects were confirmed by multiple experiments when the HLA-G was administered at an early stage of RA score. However, when we administered the HLA-G proteins to more severe CIA mice, the clear immunosuppressive effects had not been observed (data not shown).
3.3.The HLA-G dimer binds to PIR-B with an avidity effect
The binding of the HLA-G dimer to PIR-B was characterized by surface plasmon resonance (SPR). First, the HLA-G dimer was refolded as described in Materials and . In vivo, the HLA-G tetramer triggered the prolongation of allogenic graft survival, due to its immunosuppressive functions [9] . Our data revealed that the local administration of HLA-G proteins can reduce joint swelling throughout the four limbs, and the anti-RA activity persists for a relatively long time, even with a single, local intracutaneous administration at the left foot. In CIA mice, recombinant HLA-Gs would inhibit the DC maturation and the ability of antigen presentation might be down-regulated. The suppression of antigen presentation would lead to inhibition of systemic immune responses. The mechanism why the role of HLA-G could be sustained had not been clarified in this study, the inhibitin of DC maturation would affect a wide range of immune responses, thus immune tolerance could be prolonged. As expected, the HLA-G dimer exhibits stronger immunosuppressive effects than the monomer (Figures 3 and 4) . We previously reported that the signal inhibition ability of the HLA-G dimer through LILRB1 was about 100-fold higher than that of the HLA-G monomer [8] . As for PIR-B signaling, a single administration sufficiently suppressed RA symptoms at doses of 15 g for the dimer and 12 150 g for the monomer in the RA early onset group (Figure 3) , and 1.5 g for the dimer and 15 g for the monomer in the RA late onset group (Figure 4) . Thus, the HLA-G dimer can be considered to exert about 10-fold stronger immunosuppression of PIR-B signaling, as compared to the monomer. These results also suggested that the appropriate doses of HLA-G for anti-RA effects are different for the early onset group, which possesses higher disease susceptibility, and for the late onset group, with lower disease susceptibility. When the HLA-G dimer is administered in vivo, the effective dose will differ depending on various factors, such as the symptoms of RA, age, sex, body weight, etc.
We have shown that the HLA-G dimer interacts with the extracellular domain of PIR-B, and exhibits much higher affinity than the monomer and an avidity effect Based on these results, the HLA-G dimer is useful as an anti-inflammatory reagent that exerts persistent effects with small amounts. The HLA-G dimer is formed through an intermolecular disulfide bond that links Cys42 of the HLA-G heavy chain by natural oxidation [8] , and thus it is a component naturally present in vivo. In the placenta, soluble HLA-Gs produced by either secretion or proteolytic shedding from the fetal cell 
